Biotech Values

[stocksrising]

Ouch!!

https://ih.advfn.com/p.php?pid=nmona&article=93817727

07:12 AM EDT, 05/10/2024 (MT Newswires) -- MacroGenics (MGNX) late on Thursday said that five patients have died in the ongoing mid-stage study of its experimental drug to treat a type of prostate cancer, sending shares down by 65%.

Of the five patients, one died from acute myocardial infarction, one from cardiac arrest, two from pneumonitis, and one due to pleural effusion.

MacroGenics is undertaking the initial steps necessary to prepare for the potential initiation of a Phase 3 study in 2025, but the final decision to pursue the study will be based on an analysis of the final data set when available, the company said.